|
How to decide if one anticancer drug is for advanced cancer?
|
|
8
|
356
|
November 20, 2024
|
|
活性炭成为亚硝酸根来源的风险如何控制？
|
|
3
|
117
|
November 16, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
276
|
August 29, 2024
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
14
|
1013
|
August 26, 2024
|
|
DMF in API, specification limit in formulation
|
|
5
|
696
|
August 26, 2024
|
|
Control limit of Nitrosamines and N-nitroso compounds
|
|
2
|
403
|
July 8, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
182
|
June 13, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
278
|
May 31, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
913
|
March 14, 2024
|
|
🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024
|
|
5
|
1358
|
April 14, 2024
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1154
|
June 6, 2023
|
|
Nitrosamine Risk Assessments in Oligonucleotides
|
|
2
|
637
|
August 10, 2023
|